Fidelity Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$430M Buy
2,275,762
+1,474,837
+184% +$258M 0.02% 568
2025
Q4
$136M Buy
800,925
+118,789
+17% +$18.2M 0.01% 1038
2025
Q3
$89.9M Buy
682,136
+134,609
+25% +$16.1M ﹤0.01% 1232
2025
Q2
$58.1M Sell
547,527
-213,975
-28% -$23.2M ﹤0.01% 1338
2025
Q1
$94.5M Buy
761,502
+19,197
+3% +$2.5M 0.01% 1117
2024
Q4
$91.4M Sell
742,305
-93,576
-11% -$11M 0.01% 1154
2024
Q3
$93.1M Sell
835,881
-87,943
-10% -$9.64M 0.01% 1131
2024
Q2
$98.6M Sell
923,824
-36,555
-4% -$4.02M 0.01% 1044
2024
Q1
$116M Sell
960,379
-268,612
-22% -$32.9M 0.01% 997
2023
Q4
$151M Sell
1,228,991
-104,138
-8% -$13M 0.01% 859
2023
Q3
$173M Buy
1,333,129
+100,349
+8% +$13.4M 0.01% 760
2023
Q2
$153M Buy
1,232,780
+126,616
+11% +$17M 0.01% 829
2023
Q1
$162M Sell
1,106,164
-199,482
-15% -$29.5M 0.01% 795
2022
Q4
$208M Buy
1,305,646
+99,953
+8% +$14.6M 0.02% 663
2022
Q3
$161M Sell
1,205,693
-394,811
-25% -$60M 0.02% 758
2022
Q2
$250M Sell
1,600,504
-153,373
-9% -$23.6M 0.02% 620
2022
Q1
$273M Buy
1,753,877
+110,633
+7% +$16.1M 0.02% 663
2021
Q4
$209M Sell
1,643,244
-1,473,348
-47% -$194M 0.02% 789
2021
Q3
$406M Sell
3,116,592
-328,811
-10% -$49.7M 0.03% 506
2021
Q2
$612M Sell
3,445,403
-89,654
-3% -$15.5M 0.05% 371
2021
Q1
$581M Buy
3,535,057
+666,338
+23% +$110M 0.05% 379
2020
Q4
$473M Buy
2,868,719
+87,803
+3% +$13.1M 0.04% 424
2020
Q3
$397M Buy
2,780,916
+1,185,464
+74% +$147M 0.04% 390
2020
Q2
$176M Buy
1,595,452
+94,313
+6% +$10.4M 0.02% 657
2020
Q1
$150M Buy
1,501,139
+112,997
+8% +$14.6M 0.02% 610
2019
Q4
$207M Sell
1,388,142
-437,858
-24% -$59.6M 0.02% 636
2019
Q3
$234M Sell
1,826,000
-1,033,344
-36% -$139M 0.03% 578
2019
Q2
$408M Sell
2,859,344
-554,315
-16% -$74.5M 0.05% 381
2019
Q1
$488M Sell
3,413,659
-1,177,608
-26% -$154M 0.06% 315
2018
Q4
$569M Sell
4,591,267
-1,157,476
-20% -$172M 0.08% 247
2018
Q3
$967M Sell
5,748,743
-886,215
-13% -$152M 0.11% 172
2018
Q2
$1.14B Buy
6,634,958
+715,595
+12% +$117M 0.13% 150
2018
Q1
$894M Sell
5,919,363
-966,529
-14% -$142M 0.11% 191
2017
Q4
$927M Sell
6,885,892
-1,156,692
-14% -$160M 0.11% 196
2017
Q3
$1.18B Sell
8,042,584
-247,826
-3% -$37.5M 0.14% 142
2017
Q2
$1.29B Buy
8,290,410
+849,348
+11% +$130M 0.16% 125
2017
Q1
$1.08B Sell
7,441,062
-24,553
-0.3% -$3.2M 0.14% 153
2016
Q4
$814M Sell
7,465,615
-1,293,068
-15% -$144M 0.11% 197
2016
Q3
$1.06B Sell
8,758,683
-45,794
-0.5% -$6.17M 0.14% 152
2016
Q2
$1.24B Sell
8,804,477
-113,017
-1% -$16.7M 0.17% 126
2016
Q1
$1.16B Sell
8,917,494
-158,066
-2% -$19.7M 0.16% 128
2015
Q4
$1.28B Sell
9,075,560
-50,649
-0.6% -$7.02M 0.17% 120
2015
Q3
$1.21B Buy
9,126,209
+159,098
+2% +$27.4M 0.17% 122
2015
Q2
$1.58B Buy
8,967,111
+30,862
+0.3% +$5.54M 0.2% 99
2015
Q1
$1.54B Buy
8,936,249
+24,899
+0.3% +$4.27M 0.2% 110
2014
Q4
$1.46B Buy
8,911,350
+260,983
+3% +$43.3M 0.19% 113
2014
Q3
$1.39B Buy
8,650,367
+2,710,013
+46% +$417M 0.19% 113
2014
Q2
$873M Buy
5,940,354
+367,562
+7% +$51M 0.12% 184
2014
Q1
$773M Buy
5,572,792
+654,085
+13% +$98.5M 0.11% 198
2013
Q4
$623M Buy
4,918,707
+466,009
+10% +$48.2M 0.09% 254
2013
Q3
$410M Buy
4,452,698
+642,501
+17% +$51.8M 0.06% 354
2013
Q2
$262M Buy
+3,810,197
New +$233M 0.04% 477

Other funds holding JAZZ

Fidelity Investments's JAZZ Position: Q1 2026 in Review

Fidelity Investments increased its Jazz Pharmaceuticals (JAZZ) stake by 184% in Q1 2026, buying an estimated $258M and bringing the position to 2,275,762 shares worth $430M. The position accounts for 0.02% of the portfolio, ranked #568.

Fidelity Investments first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.58B in Q2 2015. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Fidelity Investments held 2,275,762 shares of Jazz Pharmaceuticals worth $430M as of Q1 2026.
  • Fidelity Investments bought 1,474,837 Jazz Pharmaceuticals shares in Q1 2026, an estimated $258M.
  • Jazz Pharmaceuticals made up 0.02% of Fidelity Investments's portfolio in Q1 2026, its #568 holding.
  • Fidelity Investments first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Fidelity Investments's Jazz Pharmaceuticals position peaked at $1.58B in Q2 2015.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.